Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia

Ronald B. Goldberg, Robert S. Rosenson, Eric Hernandez-Triana, Soamnauth Misir, Michael R. Jones

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background: A randomised, double-blind, placebo-controlled study evaluated lipid- and glucose-lowering effects of colesevelam in patients with prediabetes and primary hyperlipidaemia. We report the effect of colesevelam on lipoprotein particle concentration and particle size (determined by nuclear magnetic resonance spectroscopy) in these patients. Methods: Adults with prediabetes (World Health Organization criteria), low-density lipoprotein cholesterol(LDL-C) ≥ 100 mg/dL (≥2.6 mmol/L) and triglycerides < 500 mg/dL (<5.6 mmol/L) were randomised to colesevelam 3.75 g/day or placebo for 16 weeks. The intent-to-treat population comprised 103 colesevelam and 106 placebo recipients. Results: At the end of the study, mean reduction from baseline in total LDL particle concentration was significantly greater with colesevelam versus placebo (mean treatment difference: ?113 nmol/L; p = 0.02). Increases in total very low-density lipoprotein particle concentration (VLDL-P) and high-density lipoprotein particle concentration (HDL-P) did not differ significantly between the groups; however, with colesevelam versus placebo, there were significantly (p < 0.05) greater increases in large and medium VLDL-P and large HDL-P and reductions in small VLDL-P. Mean size increases were significantly greater with colesevelam for VLDL (mean treatment difference: 5.3 nm; p < 0.0001) and HDL (0.1 nm; p = 0.002). Conclusions: Colesevelam improved the overall atherogenic lipoprotein profile in adults with prediabetes and primary hyperlipidaemia, despite potentially less favourable changes in VLDL particles.

Original languageEnglish
Pages (from-to)256-262
Number of pages7
JournalDiabetes and Vascular Disease Research
Issue number3
StatePublished - May 2013


  • Apolipoprotein
  • colesevelam
  • lipoprotein particles
  • low-density lipoprotein
  • prediabetes
  • primary hyperlipidaemia


Dive into the research topics of 'Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia'. Together they form a unique fingerprint.

Cite this